TY - JOUR
T1 - Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy
AU - Klebanoff, Christopher A.
AU - Scott, Christopher D.
AU - Leonardi, Anthony J.
AU - Yamamoto, Tori N.
AU - Cruz, Anthony C.
AU - Ouyang, Claudia
AU - Ramaswamy, Madhu
AU - Roychoudhuri, Rahul
AU - Ji, Yun
AU - Eil, Robert L.
AU - Sukumar, Madhusudhanan
AU - Crompton, Joseph G.
AU - Palmer, Douglas C.
AU - Borman, Zachary A.
AU - Clever, David
AU - Thomas, Stacy K.
AU - Patel, Shashankkumar
AU - Yu, Zhiya
AU - Muranski, Pawel
AU - Liu, Hui
AU - Wang, Ena
AU - Marincola, Francesco M.
AU - Gros, Alena
AU - Gattinoni, Luca
AU - Rosenberg, Steven A.
AU - Siegel, Richard M.
AU - Restifo, Nicholas P.
PY - 2016/1/4
Y1 - 2016/1/4
N2 - Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell-T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory- induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell-based immunotherapies.
AB - Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell-T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory- induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell-based immunotherapies.
UR - http://www.scopus.com/inward/record.url?scp=84956642934&partnerID=8YFLogxK
U2 - 10.1172/JCI81217
DO - 10.1172/JCI81217
M3 - Article
C2 - 26657860
AN - SCOPUS:84956642934
SN - 0021-9738
VL - 126
SP - 318
EP - 334
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 1
ER -